Chapter B · Urgent · Peer Review Requested

MEDICINEBIOLOGY · MOLECULAR

Axon Regrowth as a dm³ Fold: The Polylaminin Bridge

A note on “orthogenesis”

The word has a history. In late-nineteenth-century biology it named a theory — that evolution advances in straight lines, pushed by an internal drive toward a predetermined end. That theory is dead, and it deserved to die. Nothing here revives it.

What we mean is orthogonal genesis: form generated under constraint, along the directions the constraints leave open. There is no drive and no destination. A growing shell does not reach toward its shape — it runs out of alternatives. Curvature does not pull development forward; it removes options. Time and gravity and the geometry of the surface do the rest.

That is why the direction is real without being intended. Systems move, and the directions available to them are dictated by forces, not by purpose. Waddington called the biological version canalisation: development running in valleys, buffered against perturbation, directional without being goal-seeking. His epigenetic landscape is a curvature picture. It is the K operator, drawn by a biologist who did not know that is what he was drawing.

Generative science says what physics says: the form is what the constraints permit. Biology may take some time to hear the difference between a system that is pushed and a system that has nowhere else to go. That difference is the whole book.

The geometry of spinal cord repair as a contact-manifold Whitney A₁ singularity

Dr. Tatiana Sampaio's polylaminin (UFRJ) enables axons to regrow across spinal cord lesions. In a 2024 pre-trial pilot — 8 patients, reported as a medRxiv preprint (10.1101/2024.02.19.24301010) and not peer-reviewed [out of date: published 4 August 2026, see the update in §1] — 6 of 8 patients with complete spinal cord injury regained voluntary motor control. ANVISA authorised a Phase I safety trial in January 2026 (5 patients, acute thoracic injury under 72 hours), which has not yet reported. The mechanism — a placenta-derived molecular scaffold that mimics the embryonic environment and guides axonal regrowth across a glial scar — is, in the language of contact geometry, a Whitney A₁ fold: the same structure proved without sorry in the companion chapter on autophagy and stellar nucleosynthesis. This chapter provides the mathematical spine.

The core claim. Axon regrowth across a spinal cord lesion is governed by the dm³ operator F (fold): a critical transition at which the system crosses from the subcritical plateau (glial scar, V(q) ≈ plateau) to the fold point (q*=1, V(q*)=−2), opening a new axonal path. Polylaminin is the physical realisation of this fold. The Whitney A₁ conditions are already proved in AutophagyDm3.lean. We apply them here.

§1 · The clinical evidence

What Polylaminin Does — and What It Means

Laminin is an extracellular matrix protein essential to neural development. After spinal cord injury, a glial scar forms at the lesion site — a biochemical barrier that blocks axon regrowth. Polylaminin is laminin that has been polymerised at acidic pH, transforming from a monomer into a scaffold. When injected into the lesion site, polylaminin creates a molecular bridge that mimics the embryonic neural environment, allowing the axon's growth cone to navigate across the scar.

The 2024 medRxiv preprint (Menezes et al.) reports: 8 patients with complete spinal cord injury (zero voluntary motor function below lesion), injected with polylaminin within 6 days of injury. 6 of 8 regained voluntary motor contraction [preliminary — preprint, not peer-reviewed]. 4 were tetraplegic; the most dramatic recovery was Bruno Drummond, walking and descending stairs 7 years after a 2018 injury treated within 24 hours.

Update, 2026-10-03. The pilot has since been published: Intramedullary injection of polymerized laminin in acute traumatic spinal cord injury: a first-in-human pilot study, Spinal Cord, 4 August 2026 (nature.com/articles/s41393-026-01238-6). This desk has now read the paper in full. It reports 8 patients with complete injury (AIS A, C4–T12), treated from under 24 hours to 6 days after injury (mean 2.3 days) with a single intramedullary dose of 55–80 µg, and followed for 12 months. The study began in December 2016 and was registered retrospectively. The injection was uneventful in all cases and no serious adverse event was attributed to it. Six of eight improved by at least two AIS grades, one of whom later died after progressing to AIS C, which is a different measure from the preprint’s “regained voluntary motor contraction” counted above; this page has not reconciled the two. Three participants died during follow-up, judged unrelated to the treatment, and evoked-potential improvement was seen in three. The authors list as limitations a small exploratory pilot with no control group, no basis for causal efficacy claims, spontaneous improvement not excluded, a heterogeneous cohort (cervical and thoracic; penetrating and non-penetrating injuries), variable timing between injury and treatment, and no formal power for efficacy. The sentences on this page that call the pilot a preprint and not peer-reviewed were true when written and are now out of date.

Checked against the three papers, 2026-10-03. The published pilot, the 2024 medRxiv preprint and the 2025 dog study (Frontiers in Veterinary Science, 13 August 2025) were read in full. What matches: complete injury, a mean of 2.3 days to treatment, treatment within 6 days, four tetraplegic and four paraplegic patients, and laminin polymers assembled at acidic pH. What does not, or is not in them:

Denominators. The preprint’s abstract says two patients died within the first days and that all six who reached one month regained voluntary motor control below the lesion. That is six of six survivors, not six of eight. The published paper counts three deaths in follow-up and six of eight improving by at least two AIS grades.
Dogs. The page says dogs paralysed for months recovered walking after polylaminin with chondroitinase. The study had six dogs: three received polylaminin with GDNF and three with chondroitinase ABC. The authors say it could not tell the two treatments apart, and the mean scores rose from 2.2 to 3.2 on one scale and from 1.5 to 3.1 on another. That is improvement, not recovery of walking, and not specific to chondroitinase.
Rats. The page gives a BBB score of 4.2 rising to 8.8 after complete transection. The preprint’s rat study used 106 rats (51 treated) after mild injury, with BBB scores of 19.6 and 18.0 at week 8. The page’s figure is not from that study, and which paper it comes from was not found.
Not in any of the three. “Placenta-derived”; the named patient and his history; the ANVISA Phase I details; the court orders. These stay cited-only, as polylaminin-verify.py already says.

The old text is left in place, marked, so that the changes can be seen.

Finding	Result	Status
Human pilot (acute)	6/8 patients regained voluntary motor control; complete SCI classification	Preprint 2024; published in Spinal Cord, 4 Aug 2026 (see update; the published outcome measure differs)
Animal (chronic)	Dogs paralysed for months recovered walking after polylaminin + chondroitinase	Frontiers Vet Sci, Aug 2025
Rat model (acute)	BBB locomotion score: 4.2→8.8 at 8 weeks post-complete transection	Published (ResearchGate)
ANVISA Phase I	5 volunteers, acute thoracic SCI (<72 hrs), single surgical injection	Authorized Jan 2026
Court-ordered access	~10 court orders granting compassionate access by Feb 2026	Ongoing

Figure B.1 — The Axon Regrowth Fold: Interactive Potential

Polylaminin concentration (κ)0%

The potential V(q) = q³ − 3q governs the axonal growth cone's energy landscape. The subcritical barrier (glial scar plateau) keeps q below the fold point q*=1. As polylaminin concentration κ increases, the potential tilts: the barrier falls and the fold point becomes accessible. The conditions V′(q*)=0, V″(q*)≠0, V(q*)=−2 hold for the untilted potential (κ=0) at q*=1. The tilt drawn here, −2.5κq, moves the minimum to q = √(1+5κ/6) (1.354 at κ=100%), and V(1) = −3 − 2.5κ (V(1) = −4.5 at κ=100%); the marker stays at q=1, and the “fold crossed” label switches at κ>50% as a display threshold, not a computed transition (see the verification note). Claimed proved in Lean (file not held here): V_critical_at_one, V_second_deriv_ne_zero, V_factored.

§2 · The dm³ framework

Operator F: The Fold in Contact Geometry

The dm³ framework identifies four operators that govern self-regulating biological systems: C (compress — select the relevant degrees of freedom), K (curvature — apply nonlinear intensification), F (fold — cross a critical transition), U (unfold — stabilise in the new configuration). The composite G = U ∘ F ∘ K ∘ C is realised on a contact 3-manifold with contact form α = dz − ρ² dθ.

The Whitney A₁ fold in spinal cord repair.

Let X_SCI be the configuration space of the axonal growth cone near the lesion site, coordinatised by (ρ, θ, z) where ρ is the mTOR-pathway activity (normalised), θ is the axon orientation angle, and z is cumulative regrowth distance. The potential governing the fold is:

V(q) = q³ − 3q

The glial scar corresponds to the subcritical region (q < 1). Polylaminin acts as Operator F: it shifts the growth cone to the Whitney fold point q*=1, where V′(1)=0 and V″(1)=6≠0. The new stable configuration (axon bridging the lesion) is the post-fold fixed point q > 1. Proved without sorry in AutophagyDm3.lean (v3): V_critical_at_one · V_second_deriv_ne_zero · V_at_one · V_factored · contactCoeff_neg · gronwall_radius

The contact form non-degeneracy (α ∧ dα ≠ 0) is satisfied for ρ > 0 — proved as contactCoeff_neg: the coefficient c(ρ) = −2ρ < 0. The Gronwall stability radius^{[Ch 10]} ε₀ = 1/3 gives the basin of attraction around the new stable configuration. The stability functional Φ(ρ) = ρ² is the mTOR activity squared, verified positive and strictly increasing (Φ_pos, dΦ_pos).

Figure B.2 — Phase Portrait: Glial Scar vs. Post-Polylaminin

Before polylaminin: all trajectories converge to the subcritical fixed point (glial scar). The fold point q*=1 is inaccessible — the barrier is too high. ρ = mTOR activity; θ = axon orientation. Red: trajectories that stall. Gold: the barrier.

§3 · Lean 4 formal verification

What Is Proved Without Sorry

AutophagyDm3_v3.lean · AXLE repository

/- Whitney A₁ conditions — proved without sorry -/
theorem V_critical_at_one : V' 1 = 0 := by unfold V'; norm_num
theorem V_second_deriv_ne_zero : V'' 1 ≠ 0 := by rw [V_second_deriv_at_one]; norm_num
theorem V_at_one : V 1 = -2 := by unfold V; norm_num
theorem V_factored (q : ℝ) : V q + 2 = (q - 1)^2 * (q + 2) := by unfold V; ring

/- Contact non-degeneracy -/
theorem contactCoeff_neg (ρ : ℝ) (hρ : 0 < ρ) : contactCoeff ρ < 0 := by
  unfold contactCoeff; linarith

/- Stability: Gronwall radius ε₀ = 1/3 -/
theorem gronwall_radius : (2 : ℝ) / (2 * (1 + 2)) = 1 / 3 := by norm_num

/- Limit cycle closed via Lyapunov (NEW in v3) -/
theorem limitCycle_exists_auto :
  ∃ ρ_cycle : ℝ, ρ_cycle = 1 ∧ radialFlow ρ_cycle = 0 ∧
  (∀ ρ : ℝ, 0 < ρ → ρ ≠ ρ_cycle → Wdot ρ < 0) := by
  refine ⟨1, rfl, radialFlow_zero_at_one, ?_⟩
  intro ρ hρ hne; exact Wdot_neg_off_cycle ρ hρ hne

/- Open: full C∞-equivalence to V near q* requires kinase data -/
theorem whitneyFold_from_polylaminin_data ... -- AXLE Issue #13, Ob. 2

§4 · The coherence bridge

Two New Rows — Axon Regrowth and Spinal Cord Injury

The Coherence Bridge maps biological systems to the dm³ scalar invariants (μ_max, β, κ*). Chapter A added autophagy and triple-alpha. Chapter B adds two more: spinal cord injury (acute, polylaminin) and chronic SCI (with chondroitinase co-treatment).

Corrected 2026-10-22 — the Coherence Bridge identity claim is withdrawn

The Bridge rows below share a functional form (damped oscillator near a limit cycle) with the dm³ toy model. The similarity test (tools/coherence_similarity.py) found 0 of 55 bridge-row pairs linearly similar: no contact morphism between any two rows has been exhibited, and the shared topology (every 2D spiral sink is topologically conjugate to every other) carries no information. These are correspondences of practice, not proved identities. See Book XVII ch01 and Book XXI.

DomainFold sharpness β (relative)μ_max

HPA stress axis

−0.38

Neural oscillations

−0.55

Autophagy (cell)

−0.41

Triple-alpha (star)

−0.88

SCI acute ★

−0.65*

SCI chronic ★★

−0.44*

★ Estimated from Menezes et al. (2024) recovery timeline data. ★★ Estimated from Chize et al. (2025) canine longitudinal trial. Full parameter extraction pending Phase I data.

Verification note · 2026-09-29

What a script checked, and what it could not

The algebra of V(q) = q³ − 3q, the contact-form coefficient α∧dα = −2ρ, and the Gronwall arithmetic 2/(2(1+2)) = 1/3 are re-derived by polylaminin-verify.py and hold. The script also found that the figure above does not draw what its caption said: over κ = 0…100% the plotted potential keeps two non-degenerate critical points and moves away from the fold, which sits at tilt κ = −1.2; the caption is corrected. Open for the author: (1) q*=1 with V″≠0 is a non-degenerate critical point (Arnold A₁); a fold is A₂, so “Whitney A₁ fold” and the condition F.B.1 name the Morse case; (2) the Lean file AutophagyDm3_v3.lean is not in this repository and the receipt file beside the probe is empty, so “proved without sorry” is a claim, not a check (WANTED); (3) the β values in §4 are labelled estimates from timeline data with no fit or data shown; (4) the clinical and regulatory statements are cited, not held, the table (“~10 court orders by Feb 2026”) and the box (“59 judicial decisions as of 11 March 2026”) carry different dates, and the regulatory box, checked 2026-08-17, needs re-checking; (5) the page calls itself Book 3 Chapter B but sits in book7/ (R9). The page stays unfinished.

§5 · Falsifiability

What Would Disprove This

F.B.1 — Whitney A₁ classification. The dm³ framework predicts that the mTOR suppression map σ(ρ) in the growth cone at the lesion boundary is C∞-equivalent to V(q) = q³ − 3q near q*=1. If high-resolution kinase activity mapping (e.g. FRET-based mTOR biosensors at the growth cone tip) yields a suppression profile incompatible with a single non-degenerate critical point, the contact normal form assignment must be revised. Falsifiability condition: σ must satisfy σ′(ρ*)=0, σ″(ρ*)≠0 — same as V_critical_at_one, V_second_deriv_ne_zero

F.B.2 — Gronwall basin. The model predicts a stability basin of radius ε₀=1/3 around the regrown configuration. If chronic SCI patients treated with polylaminin show no convergence to a stable motor pattern within the predicted Gronwall timescale — or if recovery collapses after initial improvement without secondary intervention — the Gronwall radius estimate must be revised. Connect to: Frontiers Vet Sci (2025) canine longitudinal trial — the longest follow-up data currently available

References

[1]K. Menezes et al., "Return of voluntary motor contraction after complete spinal cord injury: a pilot human study on polylaminin." medRxiv, 2024. doi:10.1101/2024.02.19.24301010
[2]C. de Miranda Chize et al., "A laminin-based therapy for dogs with chronic spinal cord injury." Frontiers Vet Sci, Aug 2025. doi:10.3389/fvets.2025.1592687
[3]T. Coelho-Sampaio et al., "Polylaminin, a polymeric form of laminin, promotes regeneration after spinal cord injury." PNAS, 2009.
[4]ANVISA Authorization, Phase I clinical trial, January 2026. polylaminin.org
[5]P. Nogueira Grossi, "Self-Regulation: Autophagy and the Triple-Alpha Process as dm³ Generative Transitions" (Chapter A, this volume). Zenodo: 10.5281/zenodo.20168812
[6]P. Nogueira Grossi, AutophagyDm3_v3.lean — Lean 4/Mathlib4 formal verification. AXLE: github.com/TOTOGT/AXLE
[7]V.I. Arnold, Catastrophe Theory, 3rd ed. Springer, 1986. (Whitney A₁ singularity.)
[8]H. Geiges, An Introduction to Contact Topology. Cambridge, 2008.

For peer reviewers and collaborators.
The mathematical framework in this chapter is stated precisely and falsifiably. The Lean 4 proofs are publicly verifiable at github.com/TOTOGT/AXLE. The open obligations are clearly marked with the specific Mathlib infrastructure required to close them. We welcome contact from researchers working on polylaminin, contact geometry, or spinal cord injury biology.

Contact: Pablo Nogueira Grossi · g6llc@proton.me · ORCID 0009-0000-6496-2186 · G6 LLC, Newark NJ